Outcomes of a NYC Public Hospital System Low-Threshold Tele-Buprenorphine Bridge Clinic at 1 Year

Bibliographic Data

ID21645452
AuthorsBabak Tofighi (0000-0001-7393-7564, Department of Population Health, New York University School of Medicine, New York, New York, USA, corresponding author), Jennifer McNeely (0000-0003-4601-6940, Department of Population Health, New York University School of Medicine, New York, New York, USA), Jenny Yang (0000-0002-9690-5466, Department of Population Health, New York University School of Medicine, New York, New York, USA), A Thomas (0000-0002-8730-2487, Bellevue Hospital Center), Daniel Schatz (Department of Population Health, New York University School of Medicine, New York, New York, USA), Timothy Reed (Department of Psychiatry, Bellevue Hospital Center, New York, New York, USA), Noa Krawczyk (0000-0002-7396-3938, Department of Population Health, New York University School of Medicine, New York, New York, USA)
Year2022
Volume57
Issue8
Pages1337-1340
Publication date2022-07-03
Open AccessNo
TypeARTICLE
VenueSubstance Use & Misuse (JOURNAL)
Journal identifiersISSN: 1082-6084 • E-ISSN: 1532-2491
PublisherInforma UK Limited (PUBLISHER • GB)
DOI10.1080/10826084.2022.2069269
PMID35481461
OpenAlexW4225090113
LanguageEN
Citations received1
References cited13

Background: This study evaluated clinical outcomes of a low barrier tele-buprenorphine bridge program for NYC residents with opioid use disorder (OUD) at 1 year during the coronavirus disease 2019 (COVID-19) pandemic. Methods and materials: This retrospective analysis of the NYC Health + Hospitals (NYC H + H) Virtual Buprenorphine Clinic registry assessed baseline demographic and clinical characteristics, rates of referrals to community treatment, and induction-related adverse events among city residents with OUD, from March 2020 to the end of March 2021. Results: The program enrolled 199 patients, of whom 62.3% were provided same-day visits (n = 124). Patients were enrolled in the program for a median of 14 days (range 0-130 days). Referrals sources included hospital and clinic staff (n = 83, 47.7%), word of mouth (n = 30, 17.2%), and correctional health or reentry services (n = 30, 17.2%). Induction-related adverse events were mostly limited to precipitated withdrawal symptoms (n = 21, 5%). Roughly half of patients were referred to community treatment (n = 109, 54.8%) and of those 51.4% (n = 56/109) completed at least one visit in community treatment. Discussion: Our experience indicates that a low threshold tele-buprenorphine bridge program in place of a safe and feasible approach to facilitating entry in community treatment for underserved people who use opioids in a large metropolitan area

Adverse effect · Buprenorphine · Emergency department · Family medicine · Metropolitan area · Opioid · Opioid use disorder · Psychiatry · Public health · Retrospective cohort study · Medicine · Nursing · Opioid Use Disorder Treatment · Poisoning and overdose treatments · Substance Abuse Treatment and Outcomes · Emergency Medicine · Internal Medicine

Tools

Open DOIOpen Access